Profile data is unavailable for this security.
About the company
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
- Revenue in EUR (TTM)5.25bn
- Net income in EUR343.00m
- Incorporated--
- Employees9.08k
- LocationUcb SAAllee de la Recherche, 60ANDERLECHT 1070BelgiumBEL
- Phone+32 25599999
- Fax+32 25599900
- Websitehttps://www.ucb.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz Group AG | -102.62bn | -102.62bn | 13.63bn | 23.85k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.23 | -- | -90.92 | -- | -- | -- |
| Genmab A/S | 2.38bn | 731.03m | 18.28bn | 2.29k | 24.89 | 4.13 | -- | 7.67 | 82.80 | 82.80 | 269.74 | 498.87 | 0.5297 | -- | 4.51 | 8,059,438.00 | 16.25 | 17.43 | 17.48 | 18.59 | 74.05 | -- | 30.69 | 35.87 | 12.42 | -- | 0.0301 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
| argenx SE | 1.14bn | -274.26m | 21.25bn | 1.15k | -- | 5.56 | -- | 18.64 | -4.78 | -4.78 | 20.00 | 64.34 | 0.3195 | 0.4373 | 3.72 | 992,952.80 | -7.69 | -17.65 | -8.49 | -19.79 | 90.39 | -- | -24.06 | -97.72 | 9.01 | -- | 0.0049 | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
| UCB SA | 5.25bn | 343.00m | 23.43bn | 9.08k | 68.42 | 2.55 | 22.66 | 4.46 | 1.76 | 1.76 | 26.91 | 47.30 | 0.3345 | 1.76 | 4.63 | 578,223.10 | 2.18 | 5.03 | 2.67 | 6.28 | 67.50 | 72.21 | 6.53 | 12.66 | 0.9224 | 3.14 | 0.2529 | 36.44 | -4.80 | 2.54 | -18.33 | -15.41 | -1.51 | 2.36 |
| Bayer AG | 47.64bn | -2.94bn | 27.53bn | 99.72k | -- | 0.836 | 3.69 | 0.5779 | -2.99 | -2.99 | 48.49 | 33.52 | 0.3951 | 1.43 | 4.85 | 477,693.20 | -2.44 | -1.79 | -3.34 | -2.38 | 58.54 | 59.02 | -6.18 | -4.80 | 0.8015 | 3.40 | 0.5764 | -- | -6.11 | 5.33 | -170.87 | -- | 1.19 | -47.66 |
| HALEON PLC | 13.10bn | 1.26bn | 35.13bn | 24.00k | 28.24 | -- | 47.44 | 2.68 | 0.1168 | 0.1168 | 1.21 | -- | -- | -- | -- | 468,125.00 | -- | -- | -- | -- | 61.94 | -- | 10.12 | -- | -- | 7.85 | -- | -- | 4.09 | -- | -1.04 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 17 Nov 2023 | 12.75m | 6.56% |
| Fidelity Management & Research Co. LLCas of 04 Apr 2024 | 8.74m | 4.49% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 4.49m | 2.31% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 3.52m | 1.81% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 2.69m | 1.38% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 2.02m | 1.04% |
| Schroder Investment Management Ltd.as of 29 Feb 2024 | 1.66m | 0.85% |
| BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 1.53m | 0.79% |
| Artisan Partners LPas of 31 Dec 2023 | 1.28m | 0.66% |
| Amundi Asset Management SA (Investment Management)as of 03 Apr 2024 | 981.09k | 0.50% |
